Italia markets open in 21 minutes

Dow Jones
39.806,77
-196,82(-0,49%)
Nasdaq
16.794,88
+108,91(+0,65%)
Nikkei 225
38.946,93
-122,75(-0,31%)
EUR/USD
1,0865
+0,0004(+0,03%)
Bitcoin EUR
65.581,73
+3.904,89(+6,33%)
CMC Crypto 200
1.527,98
+39,44(+2,65%)

NBIX Aug 2024 110.000 put

OPR - OPR Prezzo differito. Valuta in USD.

Aggiungi a watchlist

1,6500

0,0000

(0,00%)

In data: 02:04PM EDT. Mercato aperto.

GlobeNewswire
Sosei Heptares’ partner Neurocrine Biosciences Initiates Phase 1 Clinical Study Evaluating Effects of NBI-1117570 in Healthy Adults
NBI-1117570 is an investigational, oral, muscarinic M1/M4 selective dual agonist discovered by Sosei Heptares that may have the potential to treat neurological and neuropsychiatric conditionsNBI-1117570 is the second compound to advance into clinical development from a portfolio of selective muscarinic receptor agonists licensed by Sosei Heptares to Neurocrine following NBI-1117568, an oral, selective muscarinic M4 receptor agonist, which is in Phase 2 clinical trials as an investigational treat